UMC Utrecht researchers compared three different pneumonia treatment strategies in seven hospitals over a 90-day period. The treatments studied included a beta-lactam antibiotic, which is a traditional medicine similar to penicillin; a beta-lactam antibiotic paired with a macrolide antibiotic; and a relatively new fluoroquinolone antibiotic.
The mortality rate for all three treatment strategies was roughly 10 percent, indicating relatively no difference in their effectiveness.
The beta-lactam antibiotics, however, were less likely to cause antibiotic resistance than the other two studied strategies, according to the researchers.
More articles on antibiotics:
White House to release plan to reduce antibiotic resistance
Chlorine used in wastewater treatment may boost antibiotic resistance, study finds
Huggins Hospital partners with local farm for hormone, antibiotic-free beef
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
